Fil LTD Alnylam Pharmaceuticals, Inc. Transaction History

Fil LTD

$96.6 Billion
Q1 2025

A detailed history of Fil LTD transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Fil LTD holds 117,862 shares of ALNY stock, worth $50.7 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

117,862

Previous 22,066 434.13%

Holding current value

$50.7 Million

Previous $5.19 Million 512.96%

% of portfolio

0.03%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$233.07 - $290.7 $22.3 Million - $27.8 Million	95,796 Added 434.13%	117,862 $31.8 Million
Q4 2024 Feb 13, 2025	BUY	$232.27 - $300.43 $1.68 Million - $2.17 Million	7,236 Added 48.79%	22,066 $5.19 Million
Q3 2024 Nov 13, 2024	SELL	$233.81 - $287.01 $92,121 - $113,081	-394 Reduced 2.59%	14,830 $4.08 Million
Q2 2024 Aug 13, 2024	BUY	$143.31 - $247.0 $697,776 - $1.2 Million	4,869 Added 47.02%	15,224 $3.7 Million
Q1 2024 May 13, 2024	SELL	$146.51 - $198.2 $9.74 Million - $13.2 Million	-66,482 Reduced 86.52%	10,355 $1.55 Million
Q4 2023 Feb 13, 2024	SELL	$151.41 - $196.57 $1.99 Million - $2.58 Million	-13,131 Reduced 14.6%	76,837 $14.7 Million
Q3 2023 Nov 13, 2023	SELL	$170.77 - $211.65 $2.81 Million - $3.49 Million	-16,470 Reduced 15.47%	89,968 $15.9 Million
Q2 2023 Aug 11, 2023	SELL	$185.01 - $212.05 $4.14 Million - $4.74 Million	-22,373 Reduced 17.37%	106,438 $20.2 Million
Q1 2023 May 11, 2023	BUY	$182.66 - $235.53 $23.5 Million - $30.3 Million	128,807 Added 3220175.0%	128,811 $25.8 Million
Q4 2022 Feb 13, 2023	BUY	$185.53 - $241.31 $371 - $482	2 Added 100.0%	4 $0
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $277 - $464	2 New	2 $0

Others Institutions Holding ALNY

# of Institutions

748

Shares Held

114M

Call Options Held

851K

Put Options Held

817K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $52.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fil LTD with notifications on news.

Account